Guidelines of the Spanish Society of Cardiology on high blood pressure;Guías de práctica clínica de la sociedad española de cardiología en hipertensión arterial

Revista Espanola de Cardiologia

Volumn 53, Issue 1, 2000, Pages 86-90

  Romero, Federico Lombera ^a   Alonso, Vivencio Barrios ^a   Arcos, Federico Soria ^a   Peralta, Luis Placer ^a   Cruz Fernández, José M ^a   Abadal, Luis Tomás ^a   Padial, Luis Rodríguez ^a   González Juanatey, José R ^a  

^a NONE

Author keywords

Arterial hypertension; Evaluation; Guidelines; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CIMETIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ESTROGEN; FELODIPINE; INDOMETACIN; KETOCONAZOLE; LABETALOL; LISINOPRIL; METHYLDOPA; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; NITROPRUSSIDE SODIUM; OMEPRAZOLE; QUINAPRIL; STEROID; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL; ZOFENOPRIL;

ARTICLE; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; RISK FACTOR; ALGORITHM; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL EXAMINATION; DIURETIC THERAPY; DRUG ANTAGONISM; DRUG CHOICE; DRUG INDICATION; DRUG POTENTIATION; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; MEDICAL SOCIETY; NEUTROPENIA; PATHOPHYSIOLOGY; REVIEW; SEXUAL DYSFUNCTION; SPAIN;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 0033631759     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (128)

1. Kannel WB, Wilson WF. An update on coronary risk factors. Med Clin North Am 1995; 79: 951-957.
2. Stambler I, Stambler R, Neaton ID. Blood pressure, systolic and diastolic, and cardiovascular risks: U.S. population data. Arch Intern Med 1993; 153: 598-615.
3. Joint National Committee. The Sixth. Report of the Joint National Committee on Prevention. Detection. Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2.413-2.445.
4. Guidelines Subcommitte WHO. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Hypertension 1999; 17: 151-183.
5. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialised Countries since 1950. World Health Stat Q 1998; 41: 155-168.
6. Burt VL, Cutler JA, Higgins M, Horan MJ Labarthe D, Whelton P et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys. 1960 to 1991. Hypertension 1995; 26: 60-69.
7. Marqués-Vidal P, Tuomilenko J. Hypertension awareness, treatment and control in the community: is the «rule of halves» still valid? J Hum Hypertens 1997; 11: 213-220.
8. Banegas JR, Villar F, Pérez, de Andrés C, Jiménez R, Gil Lópeez E, Muñiz J et al. Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35-54 años. Rev San Hig Publ 1993; 67: 419-446.
9. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N et al. Home blood pressure measurement has a stronger predictive power for mortality than dose screening blood pressure measurement: a population-based observation in Ohasama. Japan. J Hypertens 1998; 16: 971-975.
10. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R et al. for the SAMPLE Study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1.464-1.470.
11. Redon J, Campos C, Narciso ML, Rodicio JL, Pasquale JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712-718.
12. Sierra A, Coca A. Evaluación clínica y diagnóstico diferencial del paciente hipertenso. En: Coca A. Sierra A, editores. Decisioncs clínicas y terapéuticas en el paciente hipertenso. Barcelona: JIMS, 1998; 59-80.
13. Asín Cardiel E, Lombera F, Barrios V. Ecocardiografía en la hipertensión arterial. En: Palma JC, Alegría E, Lombera F, editores. Hipertensión y cardiopatía hipertensiva. Madrid, 1996; 58-66.
14. Appel LJ, Moore TJ, Obarzanek E, Vollmer W, Svetkey LP, Sacks FK et al, for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1.117-1.124.
15. Singer DRJ, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension 1995; 25: 1.042-1.044.
16. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction imerven-tion on blood pressure and hypertension incidence in over weight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157: 657-667.
17. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH, Kostis J et al, for TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the Elderly (TONE). JAMA 1998; 279: 839-846.
18. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Study Group. N Engl J Med 1997; 336: 1.117-1.124.
19. Puddey IB, Beilin NJ, Rakic V. Alcohol, hypertension and the cardiovacular system: a critical appraisal. Addiction Biol 1997; 2: 159-170.
20. Law MR. Epidemiological evidence on salt and blood pressure. Am J Hypertens 1997; 10 (Supl): 42-45.
21. Cutler JA, Follman D, Alexander PS. Randomised controlled trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65 (2Supl S): 643S-651S.
22. Whelton PK, He J, Cutler JA, Brancatti FL, Appel LJ, Follman D et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. JAMA 1997; 277: 1.624-1.632.
23. Allender PS, Cutler JA, Follmann D, Cappuccio FP, Pryer J, Elliot P. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. Ann Intern Med 1996; 124: 825-831.
24. Stamler J, Caggiula AW, Grandits GA. Relation of body mass alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr 1997; 65 (Supl 8): 338-365.
25. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cesation. Lancet 1994; 343: 139-142.
26. Jennings GLR. Exercise and blood pressure: walk, run or swim? J Hypertens 1997; 15: 567-569.
27. Lindquist TL, Beilin LJ, Knuiman MW. Influence of lifestyle, coping and job stress on blood pressure in men and women. Hypertension 1997; 29: 1-7.
28. Psaty BM, Smith NL, Siscovick DS. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739-745.
29. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1.214-1.218.
30. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overviewof five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967-978.
31. Hansson L, Zanchetti A, Carruthers SG, Dalhof B, Elmfeldt D, Menard J et al, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1.755-1.762.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
33. Kaplan NM, Gifford RW Jr. Choice of initial therapy for hypertension. JAMA 1996; 275: 1.577-1.580.
34. Control de la Hipertensión Arterial en España. Ministerio de Sanidad y Consumo. Sociedad Española de Hipertensión. Madrid: IDEPSA, 1996; 1-99.
35. MRC Working Party. Medical Research Council Trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97-104.
36. Dahlöf B, Lindholnn LH, Hanssonl L, Schersten B, Ekbon T, Webster PO. Morbidity and mortality in the Swedish Trial in old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1.281-1.285.
37. The IPPPSH Collaborative Group. Cardiovascular Risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379-392.
38. Wikstrand J, Warnold J, Olsson G, Tuomiletho J, Elmfeldt D, Berglumd G, on behalf of the Advisory Commitee. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY Study. JAMA 1998; 259: 1.976-1.982.
39. Zanchetti A, Mancia G. Strategies for antihypertensive treatment decisions: how to asses benefits? J Hypertens 1997; 15: 215-216.
40. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbitity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
41. Materson BJ, Reda DJ, Cushman WCF, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921.
42. Frishman WH, Bryzinski BS, Coulson LR, De Quatro VL, Vlackkakis ND, Mroczek et al. A multifactorial trial design to asses combination therapy in hypertension: treatment with biso-prolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1.461-1.468.
43. Epstein M, Bakris G. Newer approaches antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1.969-1.978.
44. Mann SJ, Blumenfeld JD, Laragh JH. Issues, goals, and guidelines for choosing firstline and combination antihypertensive drug therapy. En: Laragh JH, Brenner BM, editores. Hypertension: pathophysiology, diagnosis and management. Nueva York: Raven Press, 1995; 2.531-2.542.
45. Setaro JF, Black HR. Refractory hypertension. N Engl Med 1992; 327: 543-547.
46. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1.328-1.331.
47. Siscovick D, Raghunathan T, Psaty B, Keopsell T, Wicklund K, Xiphong Lin M et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1.852-1.857.
48. Hoes A, Grobbee D, Lubsen J, Man in't Veld A, Van der Does E, Hofman A. Diuretics, beta-blockers, and the risk of sudden cardiac death in hypertensive patiens. Ann Intern Med 1995; 123: 481-187.
49. Kokko JP. Site and mechanism of action of diuretics. Am J Med 1984; 77 (Supl 5A): 11-17.
50. Van Zwieten PA. Alpha-adremoceptor blocking agents in the treatment of hypertension. En: Lavagh JH, Brenner BM, editores. Hypertension: pathophysiology, diagnosis and management. Nueva York: Raven Press, 1995; 2.917-2.935.
51. Neaton JD, Grimm RH, Trimas RJ, et al, for the Treatment of Mild Hyperthension (TOMH). Study Research Group. Treatment of mild hypertension study. Final results. JAMA 1993; 1.270: 713-724.
52. Prichand NBC, Cruickshand JM. Beta-blockade in hypertension: past, present and future. En: Laragh JH, Brenner BM, editores. Hypertension: pathophysiology diagnosis and management. Nueva York: Raven Press, 1995: 2.827-2.859.
53. Schnurr E, Widdman L, Glocke M, Efficacy and safety of carvedilol in the treatment of hypertension. J Cardiovasc Pharmacol 1987; 10 (Supl 11): 101-107.
54. Packer M, Briston MR, Lohn JN The effect of carvedilol on morbidity and mortality in patient with chronic heart failure. US. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1.349-1.355.
55. CIBIS II Investigators and Committess. The cardiac insufficiency Bisoprolol Study (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
56. Bühler FR. Calcium antagonists. En: Laragh JH, Brenner BH, editores. Hypertension: pathophysiology, diagnosis and management. Nueva York: Raven Press, 1995; 2.801-2.814.
57. Waeber B, Nussberger J, Brunner HR. Angiotensin converting enzyme inhibitions in hypertension. En: Laragh JH, Bremmen BM, editores. Hypertension: pathophysiology, diagnosis and management. Nueva York: Raven Press, 1995; 2.861-2.875.
58. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1.450-1.456.
59. Lewis EJ, Hunsicker LG, Bain RP, Ohde RD, for the Collaborative Study Group. The effect of the angiotensin converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329: 1.456-1.462.
60. Johnston C. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1.403-1.407.
61. Pitt B, Segal R, Martínez FA. Randomised trial of Losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study. ELITE). Lancet 1997; 349: 747-752.
62. Goodfriend TL, Elliolt ME, Catt KJ. Drug therapy: angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1.649-1.654.
63. Weben MA, Graettinger WF, Cheung DG. Centrally acting antihypertensive agents. En: Kaplan NM, Brenner BM, Laragh JH, editores. New therapeutic strategies in hypertension. Nueva York: Raven Press, 1989; 33-50.
64. Van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens 1997; 15 (Supl l): 3-8.
65. The INDIANA (Individual Data Analysis of Antihypertensive interventional trials) Project Collaborators. Gueyffier F, Boissel J-P. Boutitie F, Pocock S. Coope J, Cutler J et al. Effect of an tihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997; 28: 2.557-2.562.
66. Kostis JB, Davis BR, Cutler J, Grima RH, Berge KG, Cohen JD el al. Prevention of heart failure by antipertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 273: 212-216.
67. Flack J, Neaton J, Grimm R, Shih J, Cutler J, Ensrud K et al, for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92: 2.437-2.445.
68. Ritz E, Rambausek M, Hasslacher C, Mann J. Pathogencsis of hypertension n renal disease. Am J Nephrol 1989; 9: 85-90.
69. Krolewski AS, Canessa M, Warran JH, Laffel LMB, Christlich AR, Knowler WC et al. Predisposition to hypertension and susceptibility to renal disease in insulin dependent diabetes mellitus. N Engl J Med 1988; 318: 140-145.
70. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Cir culation 1995; 92: 1.326-1.331.
71. Alderman MH, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-598.
72. Psaty BM, Heckbert SR, Koepsell T. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
73. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1.214-1.218.
74. Ryan TJ, Anderson JL, Amman EM, Nraniff BA, Brooks NH, Califf RM et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Commitee on Management of Accute Myocardial Infarction). J Am Coll Cardiol 1996: 1.328-1.428.
75. Gibson RS, Boden WE, Calcium channel antagonists: friend or foe in postin arction patients? Am J Hypertens 1996: 9 (Supl): 172-176.
76. Hennekens CH, Albert CM, Godfried SL, Graziano JM, Buring JE. Adjuntive drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl J Med 1996; 335: 1.660-1.667.
77. Koren MJ, Devereux RB, Casale PN, Savage DD, Larugh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
78. Liao Y, Cooper RS, McGee DL, Mensah GA, Gall JK. The relative effects of left ventricular hypertension, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273: 1.592-1.597.
79. Verdecchia P, Schilllacci G, Borgioni G, Ciucci D, Gattobigio R, Zampi et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
80. a ed.). Nueva York: McGraw-Hill, 1993; 1.391-1.401.
81. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med 1996; 156: 1.789-1.796.
82. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy T et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trials. N Engl J Med 1992; 327: 669-677.
83. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1.450-1.456.
84. Cohn JN, Archivald DG, Ziesche S, Franciosa JA, Harslon WE, Tristani FE et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1.547-1.542.
85. Packer M, Bristow MR, Cohn JN, Colucci NS, Fowler MB, Gilbert EM et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1.349-1.355.
86. Australia/New Zeland Heart Failure Research Collaborative Group. Randomised placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
87. Doughty R, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560-565.
88. Pitt B, Segal R, Martínez FA, Meurer G, Cowley AJ, Thomas I et al, for the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
89. Packer M, O'Connor CM, Ghali JK, Presser L, Carson P, Belkin R et al, for the Prospective Randomized Amlodipine on morbidity and motality in severe chronic heart failure. N Engl J Med 1996; 335: 1.107-1.114.
90. Cohn JN, Ziesche S, Smith R, Anand J, Dunkman B, Loeb H et al, for the Vasodilator-Heart Failure Trial. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: VHcFT III. Circulation 1997; 96: 856-863.
91. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1.028-1.034.
92. Preston RA, Singer I, Epstein M. Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med 1996; 156: 602-611.
93. Klag MJ, Helton PK, Randall BL, Neaton JD, Brancati FL, Ford CE el al. Blood pressure and stage renal disease in men. N Engl J Med 1996; 334: 13-18.
94. Lazarus JM, Bourgoignie JJ, Buckalew VW. The modification of diet in renal disease study group. Achievment and safety of a low blood pressure goal in chronic renal disease: the modification of diet in renal disease study group. Hypertension 1997; 29: 641-650.
95. National High Blood Pressure Education Program Working Group. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 1996; 156: 1.938-1.947.
96. Bonelli FS, McKusick MA, Textor SC. Renal artery angio-plasty: technical results and clinical outcome in 320 patients. Mayo Clin Proc 1995; 70: 1.041-1.052.
97. Harden PN, MacLeod MJ, Rodgers RSC. Effect of renal artery stenting on progression of renovascular renal failure. Lancet 1997; 349: 1.133-1.136.
98. Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL, Strandness DE Jr. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertens 1996; 9: 1.055-1.061.
99. Simonson DC. Etiology and prevalence of hypertension in dia belie patients. Diabetes Care 1988; 11: 821-827.
100. Haffner SM. Insulin and blood pressure: fat or fantasy? J Clin Endocrinol Metab 1993; 76: 541-542.
101. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304-310.
102. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982; 285: 685-688.
103. Ruilope LM, Rodicio JL. Microalbuminuria in clinical practice. A current survey of world literature. Kidney 1995; 4: 211-216.
104. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the collaborative study group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993; 329: 1.456-1.462.
105. Charurvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A et al, and The Euclid Study group. Effect of Lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
106. Su HY, Sheu WH, Chin HM, Jeng CY, Chen YD, Reaven GM. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens 1995; 8: 1.067-1.071.
107. Bakris GL, Copley JB, Vicknair N, Sadler RM, Leurgans S. Calcium channel Mockers versus other antihypertensive therapies on progression of NIDDM associated nephrophaty. Kidney Int 1996; 50: 1.641-1.650.
108. UK Prospective diabetes study group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. Br Med J 1998; 317: 713-720.
109. Ruilope LM, García-Robles R. Hor far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens 1997; 15 (Supl 2): 63-65.
110. Frost PH, Davis BR, Burlando AJ for the Systolic Hypertension in the Elderly research group. Serum lipids and incidence of co-ronary heart disease: findings from the Systolic Hypertension in the Elderly. Circulation 1996; 94: 2.381-2.388.
111. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA 1997; 278: 313-321.
112. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the National High Blood Pressure Education Programm. Pediatrics 1996; 98: 649-658.
113. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275-285.
114. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401.
115. Setaro JF, Black HR. Refractory hypertension. N Engl J Med 1992; 327: 543-547.
116. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH et al, for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo -controlled European trial on isolated Systolic Hypertension in the Elderly. Lancet 1997; 360: 757.
117. SHEP Cooperative Research Group Prevention of Stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265; 3.255-3.264.
118. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
119. Hostis JB, Davis BR, Cutler J. Prevention of heart failure by an tihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212-216.
120. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialist's Colllaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatment. J Hypertens 1998; 16: 127-137.
121. National High Blood Pressure Educcation Program Working Group. National High Blood Pressure Education program Working Group Report on High Blood pressure in Pregnancy. Am J Obstet Gynecol 1990; 163: 1.689-1.712.
122. Australasian Society for the Study of Hypertension in Pregnancy. Management of Hypertension in pregnancy: executive summary. Med J Aust 1993; 158: 700-702.
123. Sibal BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257-265.
124. Lindheimer MD. Pre-eclampsia-eclampsia 1996: preventable? Have disputes on its treatment been resolved? Curr Opin Nephrol Hypertens 1996; 5: 452-458.
125. Levine RJ, for the CPEP Study group. Calcium for preeclampsia (CPEP): a double blind placebo controlled trial in healthy nulliparas. N Engl J Med 1997; 337: 69-76.
126. CLASP Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women. Lancet 1994; 343: 619-629.
127. Woods JW. Oral contraceptives and hypertension. Hypertension 1988; 11 (Supl 2): 11-15.
128. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risks factors in postmenopausal women: the postmenopausal Estrogen/Progestin Interventions. PEPI trial. JAMA 1995; 273: 199-208.